Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The investigators' in vitro data suggest that Neurokinin-1 receptor antagonists like
aprepitant will decrease the expression of CCR5, an essential co-receptor in the life cycle
of HIV, in the surface of macrophages and lymphocytes to levels at least similar to those
observed in patients heterozygous for the CCR5 32 mutation. Together with a direct potential
antiviral effect this could alter disease progression in patients with HIV infection.
The investigators' hypothesis is that aprepitant is safe, tolerable and has antiviral
activity in HIV infected individuals.
This is randomized, placebo controlled, double blind study to determine the safety and
antiviral activity of aprepitant by comparing the change in HIV RNA viral load after 2 weeks
of aprepitant monotherapy.
18 HIV infected males and females ≥ 18 years old who have early infection with CD4 cell
counts ≥ 350 cells/mm3. Subjects will be randomized 1:1 to receive 375 mg of aprepitant
(Emend®) or placebo.